EUVIMEDEUVIMED entdecken
Open Access

Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition

Wenxin Hu 胡文欣 iD, Honglin Chen 陈竑霖 iD, Steven He iD, Joshua M L Casan iD, Carolyn Shembrey, Sharon Li, Lauren M Brown iD, Andrea Zhao iD, Lynda Truong, Isabella Buchner, Dane Vassiliadis iD, Timothy P Hughes iD und 9 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.ady0296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Wenxin Hu 胡文欣 und 20 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Fusion Proteins, bcr-abl, Gene Silencing, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council, Cancer Council Victoria, Cass Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic gene fusions are key drivers of cancer, yet most remain undruggable by current therapies. Here, we establish CRISPR- Psp Cas13b as a personalizable platform for systematic silencing of various fusion transcripts. We reveal that recognition and cleavage of the breakpoint sequence by Psp Cas13b disrupt the fusion transcript, resulting in efficient protein depletion. Psp Cas13b cleavage produces aberrant, translation-incompetent target RNA species, a subset of which harbors internal deletions proximal to the cleavage site. We demonstrate that targeting the BCR::ABL1 breakpoint sequence efficiently degrades both wild-type and drug-resistant BCR::ABL1 mutants, which are the primary drivers of tyrosine kinase inhibitor resistance and relapse in chronic myeloid leukemia. Molecular profiling revealed that Psp Cas13b impairs BCR::ABL1 tyrosine phosphokinase activity and triggers extensive transcriptomic and proteomic remodeling, leading to erythroid differentiation and apoptosis in drug-resistant cells. Beyond BCR::ABL1, personalized design of Psp Cas13b effectively silences other undruggable oncogenic fusions. Collectively, this study establishes a molecular framework for precise targeting of undruggable or drug-resistant oncogenic transcripts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsFusion Proteins, bcr-ablGene SilencingOncogene Proteins, FusionHumansDrug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell Line, Tumor

Substanzen

Fusion Proteins, bcr-ablOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3052, Australia.
  • Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Parkville, Victoria, Australia.
  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, NSW Australia 2052.
  • School of Women's and Children's Health, UNSW Sydney, Sydney, NSW, Australia.
  • Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, Australia.

ORCID-Profile: Wenxin Hu 胡文欣, Honglin Chen 陈竑霖, Steven He, Joshua M L Casan, Lauren M Brown, Andrea Zhao, Dane Vassiliadis, Timothy P Hughes, Deborah L White, Antoine De Weck, Ilia Voskoboinik, Quentin Gouil, Joseph A Trapani, Paul G Ekert, Teresa Sadras, Mohamed Fareh

Förderung

  • National Health and Medical Research Council
  • Cancer Council Victoria
  • Cass Foundation
  • Australia and New Zealand Sarcoma Association
  • The Lorenzo and Pamela Galli Medical Research Trust

Zitieren

APA

Hu 胡文欣, W., Chen 陈竑霖, H., He, S., Casan, J. M. L., Shembrey, C., Li, S., Brown, L. M., Zhao, A., Truong, L., Buchner, I., Vassiliadis, D., Hughes, T. P., White, D. L., Carmichael, C. L., De Weck, A., Voskoboinik, I., Gouil, Q., Trapani, J. A., Ekert, P. G., …, & Fareh, M. (2026). Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition. Science Advances. https://doi.org/10.1126/sciadv.ady0296

Vancouver

Hu 胡文欣 W, Chen 陈竑霖 H, He S, Casan JML, Shembrey C, Li S, et al. Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition. Science Advances. 2026. doi:10.1126/sciadv.ady0296

BibTeX
@article{Hu2026,
  author = {Hu 胡文欣, Wenxin and Chen 陈竑霖, Honglin and He, Steven and Casan, Joshua M L and Shembrey, Carolyn and Li, Sharon and Brown, Lauren M and Zhao, Andrea and Truong, Lynda and Buchner, Isabella and Vassiliadis, Dane and Hughes, Timothy P and White, Deborah L and Carmichael, Catherine L and De Weck, Antoine and Voskoboinik, Ilia and Gouil, Quentin and Trapani, Joseph A and Ekert, Paul G and Sadras, Teresa and Fareh, Mohamed},
  title = {Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.ady0296}
}
Kostenlos starten →